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Background: It is generally accepted that people with chronic obstructive pulmonary disease 
(COPD) are at increased risk of vascular disease, including venous thromboembolism (VTE). 
While it is plausible that the risk of arterial and venous thrombotic events is greater still in 
certain subgroups of patients with COPD, such as those with more severe airflow limitation 
or more frequent exacerbations, these associations, in particular those between venous events 
and COPD severity or exacerbation frequency, remain largely untested in large population 
cohorts.
Methods: A total of 3,594 patients with COPD with a first VTE event recorded during January 1, 
2004 to December 31, 2013, were identified from the Clinical Practice Research Datalink dataset 
and matched on age, sex, and general practitioner practice (1:3) to patients with COPD with 
no history of VTE (n=10,782). COPD severity was staged by degree of airflow limitation (ie, 
GOLD stage) and by COPD medication history. Frequent exacerbators were defined as patients 
with COPD with $2 exacerbations in the 12-month period prior to their VTE event (for cases) 
or their selection as a control (for controls). Conditional logistic regression was used to estimate 
the association between disease severity or exacerbation frequency and VTE.
Results: After additional adjustment for nonmatching confounders, including body mass 
index, smoking, and heart-related comorbidities, there was evidence for an association between 
increased disease severity and VTE when severity was measured either in terms of lung func-
tion impairment (odds ratio [OR]
moderate:mild
 =1.16; 95% confidence intervals [CIs] =1.03, 1.32) 
or medication usage (OR
severe:mild/moderate
 =1.17; 95% CIs =1.06, 1.26). However, there was no 
evidence to suggest that frequent exacerbators were at greater risk of VTE compared with 
infrequent exacerbators (OR =1.06; 95% CIs =0.97, 1.15).
Conclusion: COPD severity defined by airflow limitation or medication usage, but not exacer-
bation frequency, appears to be associated with VTE events in people with COPD. This finding 
highlights the disconnect between disease activity and severity in COPD.
Keywords: COPD, venous thromboembolism, Clinical Practice Research Datalink, frequent 
exacerbators
Introduction
Chronic obstructive pulmonary disease (COPD), which is currently ranked fourth in 
the list of causes of global mortality,1 represents a considerable and potentially growing 
burden on health services worldwide. As it is largely a disease of middle-age, patients 
with COPD frequently present with other age- and smoking-related chronic diseases: 
comorbidities that are common in COPD thus include cardiovascular disease (CVD), 
diabetes, skeletal muscle weakness, lung cancer, osteoporosis, and depression. Of these, 
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CVD is a leading cause of morbidity and mortality among 
patients with COPD, especially among those with mild-to-
moderate disease.2,3
The close association between CVD and COPD has 
received much attention over the past 10–15 years. Although 
common risk factors (eg, smoking and aging) are undoubt-
edly important, COPD has been established as an independent 
risk factor for selected CVD outcomes, in particular myo-
cardial infarction (MI), with low-grade, chronic systemic 
inflammation proposed as the common denominator linking 
the two mechanistically.2,4 Moreover, several researchers 
have suggested that the increased risk of CVD is greater 
still in those with more severe disease5,6 and around the time 
of an exacerbation, findings which are in keeping with the 
systemic inflammation hypothesis.7
Although systemic inflammation has been identified as a 
pathologic feature of COPD at all stages of disease severity, 
experimental evidence suggests that it intensifies as lung 
function deteriorates and disease progresses.8 Similarly, 
exacerbations of COPD have been associated with acutely 
increased periods of both lung and systemic inflammation, 
thereby inducing a prothrombotic state. Furthermore, patients 
who have more “active” disease and experience frequent 
exacerbations of COPD tend to have increased airway and 
systemic inflammation, even during periods when their dis-
ease is stable.7 Collectively, these findings provide support for 
an increased CVD risk with increasing disease severity and 
a mechanism by which frequent exacerbators could have an 
increased risk of CVD relative to infrequent exacerbators.4
Although attention has focused on arterial cardiovascular 
outcomes, and on MI in particular, patients with COPD are 
believed to also be at increased risk of a range of other vas-
cular outcomes, including venous thromboembolism (VTE), 
which manifests as either deep vein thrombosis (DVT), or 
as pulmonary embolism (PE). Given that the risk factors for 
VTE are broadly similar to those for arterial thrombosis, an 
increased risk of VTE events among people with COPD is 
consistent with the aforementioned systemic inflammation 
mechanism. Although this association has been fairly well 
established in small-scale studies involving patients hospi-
talized with an acute exacerbation of COPD (AECOPD),9,10 
relatively few large-scale, population based studies of this 
type have been undertaken. Moreover, the relationships 
between VTE risk and disease severity and between VTE 
risk and exacerbation frequency have not been described in 
detail in a large population cohort.5,6,11
Using data from the UK Clinical Practice Research 
Datalink (CPRD), we therefore undertook a matched 
case–control study to investigate the profile of VTE risk in 
COPD, specifically to determine whether the risk of VTE 
disease varies according to disease severity (as measured 
by degree of airflow limitation or medication usage) or 
exacerbation frequency.
Methods
Data sources
The CPRD database contains research standard, anonymized 
longitudinal primary health care data for ~14 million patients, 
equating to ~79 million person-years of follow-up,12 and as 
such is one of the world’s largest e-health datasets. Records 
comprise coded diagnostic and clinical information, as well 
as complete prescribing information and details of referrals 
and test results. Currently, ~5.5 million people (8% of the 
population) from over 660 primary care practices located 
throughout the UK contribute data to CPRD. Patients enrolled 
in CPRD have been shown to be broadly representative of 
the UK population in terms of age, sex, and geographical 
distribution.12
study population
The study population comprised active CPRD patients with 
a diagnosis of COPD, aged at least 35 years on the date of 
their diagnosis. COPD was identified in CPRD by means of 
a validated list of Read codes.13
Case definition
Cases were all individuals in the study population who expe-
rienced a first VTE during the chosen period of study, from 
January 1, 2004 to December 31, 2013. Diagnostic Read 
codes were used to define VTE.14 The primary outcome was 
created by grouping any event with a diagnostic Read code 
for DVT or PE.
Patients not registered with CPRD at the time of their first 
VTE event (the index date), or who had ,1 year of research 
standard CPRD registration prior to their index date, were 
excluded. Individuals with a previous diagnosis of either 
DVT or PE were also excluded as the risk of a second or 
recurrent event is likely to be different from the first, as were 
any patients whose first VTE was given a prevalent code 
(Figure 1). Other exclusion criteria are noted in Figure 1.
Each identified case (n=3,594) was matched to three con-
trols (patients with COPD but without VTE); controls were 
selected at random from the pool of eligible patients with 
COPD on the date of the VTE in the case (index date). Controls 
were matched to cases (1:3) on the basis of their sex, index 
age (within 5 years), and general practitioner (GP) practice. 
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Inclusion and exclusion criteria for the controls were the same 
as those for the cases. Since the sampling of controls allowed 
replacement, controls could later become a case and could 
be selected as a control for more than one case.
Exposure definitions
Two different measures of disease severity were employed, 
the Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) staging system (which ranks patients according to 
their degree of airflow limitation) and a surrogate marker 
based on prescribing history of COPD medications. These 
include short- and long-acting β
2
-agonists and muscarinic 
antagonists, as well as inhaled and oral corticosteroids. The 
latter measure, which also categorized patients as having 
mild, moderate, severe, or very severe disease, relied on 
the NICE treatment guidelines for COPD that recommend 
different combinations of medications depending on dis-
ease severity.15 The derivation of the medications-based 
measure of disease severity from GPs’ prescribing data for 
individual patients is detailed in Supplementary material. 
Figure 1 Patient flow: selection of cases and matched controls from a source population of patients contributing data to CPRD with a diagnosis of COPD.
Abbreviations: COPD, chronic obstructive pulmonary disease; CPrD, Clinical Practice research Datalink; gP, general practitioner; VTe, venous thromboembolism.
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Given our study objectives – to define at least one of our 
main exposures solely in terms of lung function impairment 
rather than as a composite measure which combines several 
aspects of disease – the classical spirometry-only GOLD 
staging classification was used in preference to the revised 
(2011) version.16
Acute exacerbation events were also identified from 
patient records using a recently validated definition: in order 
to be classified as having had an AECOPD, patients had to 
have an exacerbation code and be prescribed a prespecified 
antibiotic or oral prednisolone, or both.17 Individuals were 
then categorized as either frequent or infrequent exacerbators 
depending on the number of exacerbations recorded in the 
12-month period prior to their index date. Those recording 
two or more exacerbations in the year preceding the index 
date were coded as frequent exacerbators and as infrequent 
exacerbators otherwise.18
Additional information was extracted from CPRD on 
demographic factors (ethnicity and socioeconomic status), 
comorbid CVD (atrial fibrillation, heart failure, peripheral 
arterial disease [PAD], acute coronary syndrome [ACS], MI, 
and angina), risk factors (body mass index [BMI categorized 
according to the standard World Health Organization clas-
sification], hypertension, diabetes, dyslipidemia, family 
history of CVD, smoking history [current, ex-, or never]), 
drug prescriptions (for antiplatelets, anticoagulants, statins, 
angiotensin converting enzyme inhibitors, angiotensin 
receptor blockers, nitrates, calcium channel blockers, and 
β-blockers, as well as a range of COPD medications), and 
coronary interventions (percutaneous coronary intervention 
or coronary artery bypass graft). For comorbid CVDs, their 
risk factors (BMI excepting) and medications, exposures 
were defined as binary variables. However, in order to be 
coded as being on a given medication, patients had to have 
been prescribed the same medication on at least two occa-
sions prior to their index date.
statistical analysis
Conditional logistic regression was used to estimate odds 
ratios (ORs) for the associations between aspects of COPD 
disease and VTE. In the first instance, regression models 
were constructed to explore the impact of COPD severity 
and various potential confounders on the odds of developing 
VTE. Similar analysis strategies were used to estimate the 
odds of experiencing a VTE event in frequent and infrequent 
exacerbators.
In the interests of avoiding problems of collinearity, 
we adjusted for the presence of selected risk factors (BMI, 
smoking, family history of heart disease, history of hyperten-
sion, dyslipidemia, or diabetes) and also for various common 
CVD comorbidities (atrial fibrillation, heart failure, PAD, 
angina, MI, and ACS), but not for prescribed medications 
for these conditions.
For the purposes of this analysis, the traditional change-
in-effect method for selecting confounders was comple-
mented with a causal inference-based approach involving the 
use of directed acyclic graphs.19 Accordingly, the regression 
analyses were – in addition to the matching variables – 
adjusted for smoking and BMI, and also for heart failure and 
a composite measure representing presence of pathologically 
similar CVD comorbidities (categorized as no CVDs, any 
one of angina, MI, PAD, and ACS or two or more of angina, 
MI, PAD, and ACS).
All analyses were conducted using STATA, version 13 
(StataCorp LP, College Station, TX, USA).
Missing data
For all variables, except GOLD stage, the proportion of miss-
ing records was ,3%. A detailed evaluation of the nature 
of missingness in GOLD stage data was conducted, com-
paring patients with and without spirometry measurements 
in their primary health record to determine if they differed 
with respect to GP practice, exposure, outcome, or potential 
confounders and whether or not these data were missing at 
random. Despite some evidence that missingness (18% in 
cases and 14% in controls) was skewed in favor of older, 
nonsmoking women from practices with a lower number 
of patients with COPD, it was concluded that the degree 
and patterns of missingness were unlikely to bias our effect 
estimates, and therefore a complete case analysis would be 
appropriate.
Power calculations
Given that VTE is a relatively rare occurrence, power cal-
culations were carried out to verify that the study would be 
sufficiently powered to detect a significant difference in the 
odds of experiencing such an event in frequent exacerba-
tors relative to infrequent exacerbators. For the purposes 
of this calculation, it was assumed (on the basis of UK 
prevalence data) that the CPRD dataset would have 306 
patients who experienced the outcome of interest (a VTE) 
and who would be classed as a frequent exacerbator. For a 
1:1 matching of cases and controls and an α of 5% (type 1 
error), the minimum and maximum detectable ORs would 
be 0.369 (highest OR ,1) and 2.036 (smallest OR .1), 
respectively.
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ethics
Ethical approval was obtained from the LSHTM ethics com-
mittee (reference: 8140), as well as the CPRD’s Independent 
Scientific Advisory Committee (ISAC) (Protocol number: 
14_108R). Written informed patient consent was deemed 
not necessary as routinely-collected anonymized electronic 
healthcare records were used for this study.
Results
A total of 3,594 subjects (1,870 men and 1,724 women) experi-
enced a VTE (as either a DVT or a PE) within the study period 
(cases). Age at first VTE ranged from 42.6 to 96.1 years; the 
mean age at VTE was 74.1 years. On average, men experienced 
their first VTE slightly earlier than women (mean age at VTE 
in women, 74.8 years; mean age at VTE in men, 73.4 years).
The characteristics of 3,594 cases and 10,782 matched 
controls (case:control ratio, 1:3) are summarized in Table 1. 
In this cohort of patients with COPD, being obese and having 
at least one heart-related comorbidity increased the risk of a 
first VTE, independently of age, sex, and GP practice.
Approximately half the control group (n=10,119) were 
classified as having “moderate” COPD (GOLD stage 2). 
A further 27% had “severe” disease (GOLD stage 3), 7% 
had “very severe” disease (GOLD stage 4), while the remain-
ing 16% were classed as having “mild” disease (GOLD 
stage 1) (Table S1). These proportions are largely similar 
in the cases. When patients’ COPD was staged according to 
their medication history, a greater proportion were catego-
rized as having severe and very severe disease (Table S2); 
whereas spirometry placed a third (34%) of the controls in 
the severe and very severe categories (GOLD stages 3+4), 
the medications-based measure put just over a half (54%) 
in these two categories. In addition, the medications-based 
staging ranked proportionally more women than men in 
the severe/very severe COPD disease categories (55.9% 
versus 53.3%).
Twenty-eight percent of the control group (and 29% 
of cases) were classed as frequent exacerbators (Table 2). 
Among the controls, women and ex-smokers were more 
likely to be frequent exacerbators. The proportion of fre-
quent exacerbators did not appear to vary markedly across 
the BMI categories, but those with underlying conditions 
such as diabetes, heart failure, and CVDs were more likely 
to experience a greater number of exacerbations. Broadly, 
similar patterns are observed among the cases (Table 2). 
Interestingly, patients with hypertension appeared to suffer 
fewer exacerbations of their COPD symptoms than those 
recording a blood pressure within the normal range.
Among the controls classed as having “severe” and “very 
severe” disease (GOLD stages 3 and 4), 31.3% and 33.3% 
were coded as frequent exacerbators, respectively, whereas 
28.5% and 27.6% of those classed as having “mild” or 
Table 1 Characteristics of cases and matched controls, and Ors 
for first VTE (univariate analyses adjusted for age, sex, and GP 
practice by matching)
Characteristic Cases Controlsa OR (95% CIs)
Number (%) Number (%)
exacerbation 
frequency
3,594 (100.0) 10,782 (100.0)
Infrequent 2,547 (70.9) 7,765 (72.0) 1
Frequent 1,047 (29.1) 3,017 (28.0) 1.06 (0.97, 1.15)
sex 3,594 (100.0) 10,782 (100.0) Matched
Men 1,870 (52.0) 5,610 (52.0)
Women 1,724 (48.0) 5,172 (48.0)
Index age (years) 3,594 (100.0) 10,782 (100.0) Matched
Under 60 268 (7.5) 800 (7.4)
60–69 876 (24.4) 2,643 (24.5)
70–79 1,418 (39.5) 4,280 (39.7)
80 and over 1,032 (28.7) 3,059 (28.4)
smoking statusb 3,593 (100.0) 10,773 (100.0)
nonsmoker 369 (10.3) 1,089 (10.1) 1.00 (0.88, 1.14)
ex-smoker 1,634 (45.5) 4,829 (44.8) 1
Current smoker 1,590 (44.3) 4,855 (45.1) 0.96 (0.89, 1.05)
BMIb 3,494 (100.0) 10,526 (100.0)
Underweight 193 (5.5) 826 (7.9) 0.83 (0.70, 0.98)
normal weight 1,109 (31.7) 3,910 (37.1) 1
Overweight 1,123 (32.1) 3,393 (32.2) 1.18 (1.07, 1.30)
Obese 1,069 (30.6) 2,397 (22.8) 1.61 (1.45, 1.77)
Family history 3,594 (100.0) 10,782 (100.0)
no 2,597 (72.3) 7,870 (73.0) 1
Yes 997 (27.4) 2,912 (27.0) 1.04 (0.95, 1.14)
hypertension 3,594 (100.0) 10,782 (100.0)
no 1,764 (49.1) 5,436 (50.42) 1
Yes 1,830 (50.9) 5,346 (49.6) 1.06 (0.98, 1.14)
Dyslipidaemia 3,594 (100.0) 10,782 (100.0)
no 2,873 (79.9) 8,541 (79.2) 1
Yes 721 (20.1) 2,241 (20.8) 0.95 (0.86, 1.05)
Diabetes 3,594 (100.0) 10,782 (100.0)
no 2,998 (83.4) 8,997 (83.4) 1
Yes 596 (16.6) 1,785 (16.6) 1.00 (0.90, 1.11)
Atrial fibrillationb 3,594 (100.0) 10,781 (100.0)
no 3,129 (87.1) 9,593 (89.0) 1
Yes 465 (12.9) 1,188 (11.0) 1.21 (1.08, 1.36)
heart failureb 3,594 (100.0) 10,780 (100.0)
no 3,059 (85.1) 9,650 (89.5) 1
Yes 535 (14.9) 1,130 (10.5) 1.52 (1.36, 1.70)
CVDs (composite)c 3,594 (100.0) 10,782 (100.0)
no CVDs 2,558 (71.2) 7,931 (73.6) 1
1 CVD 719 (20.0) 2,041 (18.9) 1.10 (1.00, 1.21)
2 or more CVDs 317 (8.8) 810 (7.5) 1.23 (1.07, 1.41)
Notes: aIncluding duplicates. since control selection was concurrent with 
replacement, some cases were picked as a control before they became a case and 
some people were selected as a control more than once. hence among the control 
group there are duplicated individuals. There are 10,119 individual controls. bsome 
missing data. cMyocardial infarction, angina, peripheral arterial disease, acute coronary 
syndrome.
Abbreviations: BMI, body mass index; CI, confidence interval; CVD, 
cardiovascular disease; gP, general practitioner; Or, odds ratio; VTe, venous 
throm boembolism.
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“moderate” disease were coded as infrequent exacerbators, 
respectively (Table 3). Similarly, when staged according 
to medication history, frequent exacerbators accounted 
for 37.4% of those classed as having “very severe” dis-
ease compared with 22.1% of those classed as having 
“mild” COPD.
The results of the regression analyses are presented 
in Table 4. After adjusting for BMI and smoking habits 
(in addition to the matching variables – age, sex, and GP 
practice), the odds of having a VTE event in those with 
GOLD stage 2 (moderate) disease were increased by 17% 
compared with those with GOLD stage 1 disease (mild) 
(OR =1.17; 95% confidence interval [CI] =1.03, 1.33). Addi-
tionally adjusting for heart-related comorbidities (CVDs and 
heart failure) did not materially affect the result (OR =1.16; 
95% CI =1.03, 1.32). The odds of experiencing a VTE did 
not increase further with increasing airflow obstruction 
(OR
GOLD3+4:GOLD1
 =1.16; 95% CI =1.02, 1.33).
Ignoring the fact that medication history tends to rank 
patients higher in terms of their disease severity than GOLD 
Table 2 Characteristics of frequent and infrequent exacerbators, separately by cases and controls
Characteristic Cases Controlsa P-valueb
Number  
of subjects
Infrequent Frequent Number  
of subjects
Infrequent Frequent
Number (%) Number (%) Number (%) Number (%)
sex 3,594 2,547 (70.9) 1,047 (29.1) 10,782 7,765 (72.0) 3,017 (28.0)
Men 1,870 1,336 (71.4) 534 (28.6) 5,610 4,105 (73.2) 1,505 (26.8)
Women 1,724 1,211 (70.2) 513 (29.8) 5,172 3,660 (70.8) 1,512 (29.2) 0.005
Index age (years) 3,594 2,547 (70.9) 1,047 (29.1) 10,782 7,765 (72.0) 3,017 (28.0)
,60 268 194 (72.4) 74 (27.6) 800 575 (71.9) 225 (28.1)
60–69 876 608 (69.4) 268 (30.6) 2,643 1,895 (71.7) 748 (28.3)
70–79 1,418 981 (69.2) 437 (30.8) 4,280 3,051 (71.3) 1,229 (28.7)
80 and over 1,032 764 (74.0) 268 (26.0) 3,059 2,244 (73.4) 815 (26.6) 0.259
smoking statusc 3,593 2,546 (70.9) 1,047 (29.1) 10,773 7,758 (72.0) 3,015 (28.0)
nonsmoker 369 276 (74.8) 93 (25.2) 1,089 779 (71.5) 310 (28.5)
ex-smoker 1,634 1,150 (70.4) 484 (29.6) 4,829 3,403 (70.5) 1,426 (29.5)
Current smoker 1,590 1,120 (70.4) 470 (29.6) 4,855 3,576 (73.7) 1,279 (26.3) 0.002
BMIc 3,496 2,478 (70.9) 1,016 (29.1) 10,526 7,563 (71.9) 2,963 (28.2)
Underweight 193 143 (74.1) 50 (25.9) 826 603 (73.0) 223 (27.0)
normal weight 1,109 783 (70.6) 326 (29.4) 3,910 2,779 (71.1) 1,131 (28.9)
Overweight 1,123 796 (70.9) 327 (29.1) 3,393 2,427 (71.5) 966 (28.5) 0.266
Obese 1,069 756 (70.7) 313 (29.3) 2,397 1,754 (73.2) 643 (26.8)
Family history 3,594 2,547 (70.9) 1,047 (29.1) 10,782 7,765 (72.0) 3,017 (28.0)
no 2,597 1,824 (70.2) 773 (29.8) 7,870 5,686 (72.3) 2,184 (27.8)
Yes 997 723 (72.5) 274 (27.5) 2,912 2,079 (71.4) 833 (28.6) 0.385
hypertension 3,594 2,547 (70.9) 1,047 (29.1) 10,782 7,765 (72.0) 3,017 (28.0)
no 1,764 1,246 (70.6) 518 (29.4) 5,436 3,863 (71.1) 1,573 (28.9)
Yes 1,830 1,301 (71.1) 529 (28.9) 5,346 3,902 (73.0) 1,444 (27.0) 0.026
Dyslipidemia 3,594 2,547 (70.9) 1,047 (29.1) 10,782 7,765 (72.0) 3,017 (28.0)
no 2,873 2,043 (71.1) 830 (28.9) 8,541 6,177 (72.3) 2,364 (27.7)
Yes 721 504 (69.9) 217 (30.1) 2,241 1,588 (70.9) 653 (29.1) 0.172
Diabetes 3,594 2,547 (70.9) 1,047 (29.1) 10,782 7,765 (72.0) 3,017 (28.0)
no 2,998 2,125 (70.9) 873 (29.1) 8,997 6,528 (72.6) 2,469 (27.4)
Yes 596 422 (70.8) 174 (29.2) 1,785 1,237 (69.3) 548 (30.7) 0.005
Atrial fibrillationc 3,594 2,547 (70.9) 1,047 (29.1) 10,781 7,764 (72.0) 3,017 (28.0)
no 3,129 2,216 (70.8) 913 (29.2) 9,593 6,912 (72.1) 2,681 (28.0)
Yes 465 331 (71.2) 134 (28.8) 1,188 852 (71.7) 336 (28.3) 0.808
heart failurec 3,594 2,547 (70.9) 1,047 (29.1) 10,780 7,763 (72.0) 3,017 (28.0)
no 3,059 2,178 (71.2) 881 (28.8) 9,650 6,992 (72.5) 2,658 (27.5)
Yes 535 369 (69.0) 166 (31.0) 1,130 771 (68.2) 359 (31.8) 0.003
CVDs 3,594 2,547 (70.9) 1,047 (29.1) 10,782 7,765 (72.0) 3,017 (28.0)
no CVD 2,558 1,817 (71.0) 741 (29.0) 7,931 5,770 (72.8) 2,161 (27.3)
1 CVD 719 507 (70.5) 212 (29.5) 2,041 1,450 (71.0) 591 (29.0)
2 or more CVDs 317 223 (70.4) 94 (29.7) 810 545 (67.3) 265 (32.7) 0.003
Notes: aIncluding duplicates. bThe reported P-value is for the association between exacerbation frequency and the listed covariate in the control group. Values in bold indicate 
significantly increased odds in frequent exacerbators compared with infrequent exacerbators. csome missing data.
Abbreviations: BMI, body mass index; CVD, cardiovascular disease.
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staging, the effect estimates for the alternative measure of dis-
ease severity were of the same order of magnitude (“crude” 
OR
severe:mild/moderate
 =1.16; 95% CI =1.07, 1.26). Again, the fully 
adjusted ORs were very similar to the “crude” estimates (ie, 
those adjusted for the matching variables only) (adjusted 
OR
severe:mild/moderate
 =1.17; 95% CI =1.06, 1.26). However, 
in contrast to GOLD staging, there is evidence of a dose–
response relationship in the association between VTE risk 
and increasing disease severity (Table 4).
The OR for the association between exacerbation 
frequency and VTE, adjusted for the matching variables 
only, was 1.06 (95% CIs =0.97, 1.15). This result was not 
altered by adjusting for smoking and BMI (OR =1.06; 95% 
CIs =0.97, 1.15) or additionally for heart-related comorbidi-
ties (OR =1.05; 95% CIs =0.96, 1.14). There was no evidence 
of effect modification by either sex, age, BMI, or smoking.
Discussion
This study investigated the effect of both COPD sever-
ity and exacerbation frequency on VTE risk using a large 
population-based cohort of GP-diagnosed patients with 
COPD. Our analyses provided good evidence that VTE risk 
increases with worsening disease, independently of age, sex, 
BMI, smoking status, and selected comorbid CVDs. We 
would anticipate that people with more severe disease, which 
we defined according to airflow limitation (GOLD stage) 
and also by medication history, would be more susceptible 
to VTE, and thus our finding is not unexpected. Whether 
this is due to higher levels of systemic inflammation or 
increased immobility, or a combination of both, is not clear 
from these data.
As staging people according to their history of use of 
COPD medications captures slightly different aspects of 
COPD disease than the classical spirometry-based GOLD 
system, we would not necessarily expect to see close corre-
spondence in terms of the magnitude of the effect estimates. 
However, aside from the fact that medication-based staging 
tends to rank patients higher in terms of their disease severity 
than GOLD staging, the effect estimates for our two alternative 
measures of disease severity were in broad agreement, 
Table 3 Percentage of frequent exacerbators with mild, moderate, severe, and very severe disease (based on the control 
group only)
GOLD stage Medication-based staging
1 2 3 4 1 2 3 4
Total number of subjects 1,149 4,378 2,404 614 2,691 1,908 3,898 1,614
number of frequent exacerbators 374 1,208 753 203 594 541 1,076 604
Frequent exacerbators as % of total 28.5 27.6 31.3 33.1 22.1 28.4 27.6 37.4
Abbreviation: gOlD, global Initiative for Chronic Obstructive lung Disease.
Table 4 summary of main results
Disease measure Crudea ORs Adjustedb ORs Adjustedc ORs
OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value
exacerbation frequency
Infrequent 1 1 1
Frequent 1.06 (0.97, 1.15) 0.18 1.06 (0.97, 1.15) 0.22 1.05 (0.96, 1.14) 0.29
GOLD (FEV1) staging
Mild 1 1 1
Moderate 1.15 (1.01, 1.30) 0.031 1.17 (1.03, 1.33) 0.013 1.16 (1.03, 1.32) 0.018
severe/very severe 1.08 (0.94, 1.23) 0.280 1.16 (1.02, 1.33) 0.030 1.14 (1.00, 1.31) 0.058
Medication-based staging
Mild/moderate 1 1 1
severe 1.16 (1.07, 1.26) 0.001 1.16 (1.07, 1.27) 0.001 1.17 (1.06, 1.26) 0.001
Very severe 1.52 (1.37, 1.69) 0.001 1.54 (1.38, 1.72) ,0.001 1.52 (1.37, 1.69) ,0.001
Notes: aAdjusted for age, sex, and GP practice (matching variables). bAdjusted for age, sex, GP practice, BMI, and smoking habits. cAdjusted for age, sex, GP practice, BMI, 
smoking habits, CVDs [composite measure], and heart failure. To avoid having a small number of subjects in the reference category and thus compromising the precision of 
the effect estimates, the normal weight category (as opposed to underweight) was selected as the baseline for BMI and ex-smokers (as opposed to never smoked) the baseline 
for the smoking status variable in all regression models. Having examined the distribution of subjects among the disease severity categories as part of the descriptive analysis, 
the “severe” and “very severe” categories (GOLD stage 3+4) were collapsed into one (when disease is staged by spirometry, less than 10% of patients are categorized 
as having very severe disease). likewise, in the case of the alternative, proxy measure of disease severity based on COPD medication history, the categories “mild” and 
“moderate” were collapsed into a single category (this then becomes the reference category).
Abbreviations: BMI, body mass index; CI, confidence interval; CVD, cardiovascular disease; FEV1, forced expired volume in 1 second; gOlD, global Initiative for Chronic 
Obstructive lung Disease; gP, general practitioner; Or, odds ratio.
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strengthening our support for the hypothesis that having more 
severe, ie, more advanced, COPD increases risk of VTE.
Conversely, we found no evidence of an association 
between exacerbation frequency and VTE in either a crude 
matched analysis (matching on age, sex, and GP practice) or 
after adjusting for additional confounders, including BMI, 
smoking status, and selected heart-related comorbidities.
That we observe an increased VTE risk in patients with 
more advanced disease but not in those with a more active 
disease profile (frequent exacerbators) is somewhat surpris-
ing and contrary to current thinking about the mechanisms 
linking COPD and vascular disease risk. The period during 
and immediately after an exacerbation has been identified as 
especially high risk for acute cardiovascular events such as 
MI and stroke.7 It follows that VTE risk may also be height-
ened during this time. Studies have repeatedly demonstrated 
that VTE prevalence, and that of PE in particular, is relatively 
high among those hospitalized for AECOPD, as high as one 
in four according to Rizkallah et al.10 This observation, in 
combination with a plausible biological mechanism linking 
AECOPD (an acute inflammatory event in the lungs) with 
endothelial dysfunction, atherosclerotic plaque instability, 
and acute vascular events (both venous and arterial), has 
lead several authors to hypothesize that frequent exacerba-
tors (relative to infrequent exacerbators) are at increased 
risk of VTE.
Our apparently counterintuitive result draws attention 
to a concept that in recent years has gained ground in the 
COPD literature, namely, the need to distinguish more clearly 
between the “severity” and “activity” of disease.20 Several 
studies have demonstrated the disconnect between activity 
and severity in COPD: for instance, Calverley et al21 showed 
that, on average, individuals with “moderate” disease (GOLD 
stage 2) had higher rates of forced expired volume in 1 second 
(FEV
1
) decline than those classed as having “severe” or “very 
severe” disease (GOLD stage 3+4). Thus, among the COPD 
population, there will be patients who have active but not 
necessarily severe disease and vice versa. This is reflected in 
our study population, as in others,16,18 where it is noticeable 
that a substantial proportion of frequent exacerbators are 
found across all categories of disease severity, irrespective 
of the method of staging disease (Table 3).
In light of our findings, we posit that disease severity – as 
opposed to activity – is likely to be the more important deter-
minant and a better predictor of VTE risk in COPD. More-
over, in view of the strong evidence of associations between 
the cardiovascular comorbidities and disease severity, we 
suggest that the presence of cardiovascular comorbidities 
coupled with increased immobility, a common manifestation 
of advanced COPD and a known risk factor for VTE, are the 
key contributors – as opposed to frequent exacerbations – to 
the elevated VTE risk in COPD.
Comparison with other studies
Many previous studies have tended to focus on prevalent 
disease rather than incidence of new cases of CVD in COPD, 
and by concentrating on the latter, our study offers a different 
perspective. In one of the first studies to investigate VTE in 
a large cohort of patients with COPD, Kim et al6 report an 
increased prevalence of VTE among COPDGene study par-
ticipants with GOLD stage 2–4 disease relative to those who 
were classed as having normal or near normal lung function. 
In addition, among their GOLD stage 2–4 participants, those 
with a higher BMI, a shorter 6-minute walk distance, conges-
tive heart failure, PAD, or pneumothorax were more likely 
to experience a VTE, a finding that adds weight to our con-
clusion. However, as the authors themselves acknowledge, 
their diagnosis of VTE was based on self-report, whereas we 
relied on GP-recorded diagnoses. Interestingly, the number 
of exacerbations was greater in the group of COPDGene 
study participants with a self-reported history of VTE than 
in those without.
Schneider et al5 have also conducted a comprehensive 
analysis of CVD outcomes in COPD, again using the UK-
based CPRD dataset. PE and DVT were among the outcomes 
investigated, and the authors reported strong evidence of an 
association between COPD and the risk of developing PE 
but not DVT. They also investigated the effect of disease 
severity (as defined by treatment history and categorized as 
mild, moderate, and severe) on the risk of developing PE and 
DVT in a nested case–control analysis. Although the authors 
report a significant increase in PE risk across all categories 
of severity, especially in those in the most severe disease 
category (ie, on oxygen therapy), the conclusions that may 
be drawn were compromised by the small numbers involved 
(less than ten cases).
In our analysis, we found that the increase in VTE risk 
between patients with GOLD stage 2 versus GOLD stage 
1, and GOLD stage 3+4 versus GOLD stage 1 was of the 
same order of magnitude (~17%), implying the existence 
of a threshold value, a certain degree of lung function 
deterioration that is associated with increased VTE risk 
but beyond which risk does not increase (as opposed to a 
dose–response relationship). Our alternative analysis, which 
relied on medication history to stage disease severity – as 
did Schneider et al’s study5 – did not replicate this finding. 
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The reason for this difference may well be medication-
related: it is plausible that some patients with COPD, espe-
cially those with more symptomatic and advanced disease are 
being prescribed medications (for the relief of their COPD 
symptoms and management of their comorbidities) that carry 
an inherent risk of clotting and/or arrhythmias, which may 
in themselves lead to a progressive increased risk of VTE. 
Alternatively, the difference in the VTE risk relationships 
might be a reflection of the disconnect between impaired lung 
function and symptomatic disease; medication-based mea-
sures of disease severity will tend to place those with more 
symptomatic disease (eg, pronounced cough and breathless-
ness) in progressively higher disease severity categories as 
their disease progresses and their symptoms worsen. These 
highly medicated, symptomatic individuals will probably also 
have multiple comorbidities and limited exercise capacity, 
putting them at increased risk of VTE. On the other hand, not 
all individuals with pronounced lung function impairment 
will have highly symptomatic disease (lung function and 
symptoms are not always highly correlated) and may not 
necessarily be at high risk of VTE.
strengths and weaknesses
The main strength of this analysis is its large sample size; 
the use of electronic health records provides a large cohort of 
nationally representative patients for whom detailed, validated 
health data are available. The identification of patients with 
COPD in CPRD has been validated in a previous study,13 as 
has AECOPD.17 Coding of VTE events is also likely to be 
relatively free from problems caused by misclassification, 
nor do we have any reason to suspect that VTE events will be 
captured any more or less reliably among the groups of indi-
viduals defined by the main exposure categories. However, it is 
possible that patients with mild COPD, and who less likely to 
seek health care, are underrepresented in our study cohort.
The potential for residual or unmeasured confounding due 
to variables not included in the analysis is perhaps a more 
significant weakness. Matching on GP practice provides a 
means, at least partially, of controlling for some unmeasured 
and hard-to-measure risk factors, such as GP attitudes to 
treatment and management of COPD, socioeconomic status, 
and exposure to environmental factors. However, there are 
a number of potential confounders that we were unable to 
adjust for in this study. Among those of primary concern are 
additional risk factors for VTE, including the presence of can-
cer, hospitalization for various types of surgery, prescription 
of hormone replacement therapy, and pregnancy. Given the 
age of the study population (predominantly aged 60 years 
and over), it is unlikely that any subjects are pregnant. The 
number of women on hormone replacement therapy is likely 
to be low, but any distributional differences between cases 
and controls will possibly be captured by controlling for GP 
practice. If it can be assumed that the proportion of subjects 
with cancers is the same in both the cases and the controls 
(more likely to be true of lung cancers than other cancers 
given the study population all have COPD), then the pres-
ence of cancer will not confound the association. However, 
as this is far from certain, the ability to control for cancer 
would be desirable, as would be controlling for various types 
of surgery known to be high risk of VTE. Factors that would 
also merit further investigation in future studies involving this 
patient population include use of other medications that may 
potentially influence the risk of developing VTE and the role 
of the long-term management of atrial fibrillation.
Conclusion
The key finding to emerge from this study is that while risk 
of VTE in COPD increases with increasing disease sever-
ity, it does not appear to be associated with exacerbation 
frequency.
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